Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker-Guided Early Elarithromycin Treatment to Prevent Sepsis Progression in Community-Acquired Pneumonia: The React Randomized Clinical Trial

NCT06294600 is registered in ClinicalTrials.gov with Hellenic Institute for the Study of Sepsis as lead sponsor.

NCT NCT06294600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06294600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker-Guided Early Elarithromycin Treatment to Prevent Sepsis Progression in Community-Acquired Pneumonia: The React Randomized Clinical Trial
Lead sponsor
Hellenic Institute for the Study of Sepsis
Phase
Phase 3
Overall status
Recruiting
Start date
February 12, 2024
Completion date
July 30, 2026
Enrollment
330 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

community-acquired pneumonia